Research use only. This page is education, not medical advice. Eloralintide is an investigational drug that no regulator has approved. This site does not sell eloralintide and gives no dosing or administration guidance.

Short answer: Eloralintide (LY3841136) is Eli Lilly’s investigational, selective amylin receptor agonist, built to activate the AMY1 receptor far more strongly than AMY3 or the calcitonin receptor. In its 48-week Phase 2 trial it produced efficacy-estimand weight reductions of 9.5% to 20.1% versus 0.4% for placebo, and it has since moved into Phase 3-stage development, with primary completion for the lead obesity trials estimated between January and June 2028. It is not approved anywhere and is not available for human use outside registered clinical trials.

• EC50 of 23.9 pM at the human AMY1 receptor versus 253.8 pM at AMY3 — roughly a 10-fold selectivity margin (Briere et al., Mol Metab. 2025).
• Half-life after a single dose runs 12.9 to 15.3 days, about twice cagrilintide’s, though every published trial has still used once-weekly dosing.
• Combined with tirzepatide in people with type 2 diabetes (the “EloraTZP” program), it produced a reported -23.3% weight change plus an A1C reduction, greater than tirzepatide 15mg alone.
• In obese rats, 86% to 91% of weight lost was fat at low and mid doses, versus 63% for cagrilintide at its test dose — a preclinical signal only, not confirmed in humans.

Last verified October 2026. Sources are listed at the end. For laboratory and research use only. Nothing here is medical or legal advice.

Identity and molecular profile

Eloralintide, also known by its development code LY3841136, is an investigational peptide developed by Eli Lilly and Company. It is not approved by the FDA or any other regulatory body, and it is not available for purchase, prescription, or human or veterinary use. Its CAS number is 2883634-40-8, it has a molecular weight of approximately 4,526 Da, and its molecular formula is C201H319N49O65S2.

Mechanism of action

Eloralintide is classified as a selective amylin receptor agonist. Published pharmacology data report an EC50 of 23.9 pM at the human AMY1 receptor and 253.8 pM at the human AMY3 receptor, indicating a strong preference for the AMY1 subtype (Briere et al., Mol Metab. 2025;102:102271). This selectivity is the main feature that distinguishes it from non-selective amylin analogs such as cagrilintide, which activates both amylin and calcitonin receptors. A fatty-diacid modification attached to the peptide backbone is reported to extend its duration of action, supporting once-weekly dosing in clinical trials. Its terminal half-life after a single dose has been reported at 12.9 to 15.3 days — about double cagrilintide’s — though no registered study has tested a dosing interval longer than once weekly.

Amylin, the native hormone eloralintide is designed to mimic, acts through the area postrema, a circumventricular organ outside the blood-brain barrier, and interacts with hypothalamic circuits distinct from the ones targeted by GLP-1 receptor agonists like semaglutide or dual GIP/GLP-1 agonists like tirzepatide. Lilly has stated that eloralintide’s mechanism differs from tirzepatide’s, and the two are being evaluated both as standalone therapies and in combination under the “EloraTZP” program.

Clinical trial status

Eli Lilly’s Phase 2 trial (ClinicalTrials.gov identifier NCT06230523) randomized 263 adults with obesity or overweight, without type 2 diabetes, across U.S. sites to placebo or one of several once-weekly eloralintide dose arms over 48 weeks. Results were presented at ObesityWeek 2025 and published in The Lancet (Billings et al., 2025; DOI 10.1016/S0140-6736(25)02155-5). According to Lilly’s November 6, 2025 press release, all active-dose arms met the trial’s primary endpoint, with efficacy-estimand mean weight reductions ranging from 9.5% to 20.1%, compared with 0.4% for placebo. The most frequently reported adverse events were mild to moderate nausea and fatigue.

A separate Phase 2b trial testing eloralintide combined with tirzepatide (“EloraTZP”) in adults with obesity and type 2 diabetes reported, per Lilly’s September 30, 2026 release, a -23.3% weight change alongside a greater A1C reduction than tirzepatide 15mg alone — the first published readout of the combination approach.

Following the Phase 2 readout, Lilly moved eloralintide into Phase 3-stage development. Registered studies include an obstructive sleep apnea trial (NCT07369011), a knee osteoarthritis pain study, a pharmacokinetic study in healthy participants (NCT07701083), and five ENLIGHTEN-branded Phase 3 obesity trials with estimated primary completion between January and June 2028 on public ClinicalTrials.gov records.

What eloralintide is not

Eloralintide is not an FDA-approved medication, and it is not a GLP-1 drug — it does not activate the GLP-1 receptor at all. It is not sold, prescribed, or available for human or animal use anywhere in the world as of this writing, and on current public trial timelines, a filing is unlikely before 2028 or 2029 at the earliest. Any product marketed online as “eloralintide” for personal use should be treated with significant caution, since no approved commercial supply chain for this compound currently exists, and independent testing of research-market peptide vials has repeatedly found measured content diverging from label claims. This site does not sell eloralintide and does not provide dosing or administration guidance of any kind; it exists solely to track and summarize the publicly available research record.

Sources

All sources read and verified October 2026.

• Billings LK, et al. Eloralintide Phase 2. The Lancet 2025. DOI: 10.1016/S0140-6736(25)02155-5. ClinicalTrials.gov NCT06230523.
• Briere DA, et al. Molecular Metabolism 2025. PMC12640043.
• Bhattachar S, et al. Diabetes, Obesity and Metabolism 2026. PMC12992164.
• Eli Lilly. EloraTZP Phase 2b release, September 30, 2026: PR Newswire.
• ClinicalTrials.gov, eloralintide (LY3841136) records: search.